Pharmacogenetics of graft-versus-host disease: a path to personalized medicine

Area of Science:

• Hematology
• Immunology
• Pharmacogenetics

Background:

• Graft-versus-host disease (GvHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT).
• Current GvHD prophylaxis and treatment strategies require continuous improvement to reduce morbidity and mortality.
• Personalized medicine approaches are increasingly important in optimizing patient care.

Purpose of the Study:

• To review the role of pharmacogenetic variants in the prophylaxis and management of GvHD.
• To explore how pharmacogenetics can personalize GvHD treatment strategies.
• To highlight the need for integrating pharmacogenetics into clinical practice for GvHD.

Main Methods:

• Literature review of pharmacogenetic studies related to GvHD.
• Analysis of pharmacogenetic variants influencing key GvHD drugs: calcineurin inhibitors, methotrexate, mycophenolate mofetil, cyclophosphamide, and corticosteroids.
• Synthesis of current evidence on pharmacogenetics in GvHD prophylaxis and treatment.

Main Results:

• Pharmacogenetic variants significantly impact the efficacy and toxicity of GvHD prophylactic and therapeutic agents.
• Specific genetic profiles can predict patient response and risk of adverse events to certain immunosuppressants.
• Personalized drug selection and dosing based on pharmacogenetics holds promise for improved GvHD outcomes.

Conclusions:

• Pharmacogenetics offers a powerful tool for tailoring GvHD prophylaxis and treatment, moving towards precision medicine in HSCT.
• Further pharmacogenetic association studies are essential to expand the evidence base.
• Clinical implementation of pharmacogenetic testing is crucial for optimizing GvHD management and patient care.